Strides Pharma Science Ltd. - Research Center
532531 STAR Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 90.30 | 89.79 | 89.68 | 89.57 | 89.55 |
| Share application money | 2.32 | 2.45 | 4.72 | 5.72 | 7.57 |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 3,362.43 | 3,314.44 | 3,153.66 | 3,079.88 | 3,159.68 |
| Loan funds | |||||
| Secured loans | 1,349.20 | 1,244.63 | 841.04 | 852.46 | 808.95 |
| Unsecured loans | - | - | - | - | - |
| Total | 4,804.26 | 4,651.32 | 4,089.10 | 4,027.62 | 4,065.75 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 1,058.56 | 1,042.53 | 999.08 | 886.05 | 776.49 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 462.00 | 425.62 | 354.59 | 270.38 | 202.87 |
| Net block | 596.56 | 616.91 | 644.49 | 615.67 | 573.61 |
| Capital work-in-progress | 55.38 | 55.72 | 110.67 | 108.81 | 122.46 |
| Investments | 2,491.77 | 2,399.76 | 2,394.65 | 2,170.57 | 2,148.87 |
| Net current assets | |||||
| Current assets, loans & advances | 2,476.03 | 2,361.47 | 2,071.52 | 1,780.20 | 1,817.85 |
| Less : current liabilities & provisions | 815.49 | 782.54 | 1,132.24 | 647.63 | 597.05 |
| Total net current assets | 1,660.55 | 1,578.93 | 939.29 | 1,132.58 | 1,220.80 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 4,804.26 | 4,651.32 | 4,089.10 | 4,027.62 | 4,065.75 |
| Notes: | |||||
| Book value of unquoted investments | - | - | - | - | - |
| Market value of quoted investments | - | - | - | - | 154.29 |
| Contingent liabilities | 632.08 | 2,345.08 | 1,929.34 | 3,498.11 | 5,766.31 |
| Number of equity sharesoutstanding (Lacs) | 903.03 | 897.90 | 896.81 | 895.65 | 895.49 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis